Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.